Source: Eur Respir J, 51 (6) 1702638; 10.1183/13993003.02638-2017
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Anna R. Hemnes, Anandharajan Rathinasabapathy, Eric A. Austin, Evan L. Brittain, Erica J. Carrier, Xinping Chen, Joshua P. Fessel, Candice D. Fike, Peter Fong, Niki Fortune, Robert E. Gerszten, Jennifer A. Johnson, Mark Kaplowitz, John H. Newman, Robert Piana, Meredith E. Pugh, Todd W. Rice, Ivan M. Robbins, Lisa Wheeler, Chang Yu, James E. Loyd, James West. A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension. Eur Respir J, 51 (6) 1702638; 10.1183/13993003.02638-2017

Member's Comments

No comment yet.

Related content which might interest you: Polymorphisms in angiotensin converting enzyme gene are associated with risk of development of and disease severity in scleroderma-related pulmonary arterial hypertension Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms Year: 2012 Phosphodiesterase 1 upregulation in pulmonary arterial hypertension – target for anti-remodeling therapy Source: Eur Respir J 2006; 28: Suppl. 50, 159s Year: 2006 Current medical therapies in pulmonary arterial hypertension Source: Eur Respir Mon 2012; 57: 26-41 Year: 2012 The role of combination therapy in managing pulmonary arterial hypertension Source: Eur Respir Rev 2014; 23: 469-475 Year: 2014 Differences in the activity of the angiotensin converting enzyme 2 axis in patients with idiopathic pulmonary arterial hypertension and congenital heart defect related pulmonary hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 The role of angiotensin converting enzyme gene polymorphism in pulmonary thromboembolism Source: Annual Congress 2004 - Pulmonary embolism Year: 2004 Angiotensin-converting enzyme genotype modulates pulmonary artery pressure in COPD Source: Eur Respir J 2004; 24: Suppl. 48, 560s Year: 2004 The use of combination therapy in pulmonary arterial hypertension: new developments Source: Eur Respir Rev 2009; 18: 148-153 Year: 2009 Predictors of response to phosphodiesterase-5 inhibitors in pulmonary arterial hypertension Source: Virtual Congress 2021 – Therapy of pulmonary hypertension Year: 2021 Etiology specific reductions in pulmonary endothelial angiotensin converting enzyme activity in patients with PAH Source: Eur Respir J 2006; 28: Suppl. 50, 658s Year: 2006 Survivin inhibition as a potential target for pulmonary arterial hypertension Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench Year: 2019 Targeting HIF2a-ARNT hetero-dimerisation as a novel therapeutic strategy for pulmonary arterial hypertension Source: Eur Respir J, 57 (3) 1902061; 10.1183/13993003.02061-2019 Year: 2021 Beta 3 adrenoceptor: a potential therapeutic target for pulmonary arterial hypertension Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020 Spermine promotes pulmonary vascular remodelling and its synthase is a therapeutic target for pulmonary arterial hypertension Source: Eur Respir J, 56 (5) 2000522; 10.1183/13993003.00522-2020 Year: 2020 Effects of a novel azaindole-based Rho-kinase inhibitor on hemodynamics and pulmonary vascular remodelling in experimental pulmonary hypertension Source: Annual Congress 2009 - Pathobiology of pulmonary vascular diseases Year: 2009 Comparison of acute hemodynamic effects of three different phosphodiesterase inhibitors in patients with pulmonary arterial hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 705s Year: 2004 HDAC inhibitor quisinostat reduces pulmonary vascular remodeling in experimentally induced pulmonary arterial hypertension Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors Source: Eur Respir J, 50 (3) 1602425; 10.1183/13993003.02425-2016 Year: 2017 The future of treatment for pulmonary arterial hypertension Source: ERS Skills course - Pulmonary hypertension and pulmonary vascular disease Year: 2018 The future of treatment for pulmonary arterial hypertension Source: ERS Course 2017 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2017